Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Amsden GW | Pharmacological considerations in the emergence of resistance. | 1999 | Int. J. Antimicrob. Agents | pmid:10204634 |
Retsema JA | Susceptibility and resistance emergence studies with macrolides. | 1999 | Int. J. Antimicrob. Agents | pmid:10204635 |
Scaglione F et al. | Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin. | 1999 | Br J Clin Pharmacol | pmid:10215750 |
Khan AA et al. | Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. | 1999 | Int. J. Antimicrob. Agents | pmid:10221415 |
Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
Ouadrhiri Y et al. | Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. | 1999 | Antimicrob. Agents Chemother. | pmid:10223943 |
Könönen E et al. | beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. | 1999 | Antimicrob. Agents Chemother. | pmid:10223950 |
Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
Akova M et al. | In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. | 1999 | Antimicrob. Agents Chemother. | pmid:10223958 |
Gorenek L et al. | The diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea. | 1999 Jan-Feb | Hepatogastroenterology | pmid:10228818 |
Taylor H | Towards the global elimination of trachoma. | 1999 | Nat. Med. | pmid:10229224 |
Lietman T et al. | Global elimination of trachoma: how frequently should we administer mass chemotherapy? | 1999 | Nat. Med. | pmid:10229236 |
Nowicki M et al. | Partial regression of advanced cyclosporin-induced gingival hyperplasia after treatment with azithromycin. A case report. | 1998 | Ann. Transplant. | pmid:10234432 |
Carbon C and Poole MD | The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. | 1999 | J Chemother | pmid:10326741 |
Cazzola M et al. | Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. | 1999 | J Chemother | pmid:10326742 |
Petitta A et al. | Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. | 1999 | Pharmacotherapy | pmid:10331829 |
Cammarota G et al. | Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. | 1999 | Eur J Gastroenterol Hepatol | pmid:10333196 |
Wirnsberger GH and Pfragner R | Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman. | 1999 | Transplantation | pmid:10342326 |
Girgis NI et al. | Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. | 1999 | Antimicrob. Agents Chemother. | pmid:10348767 |
Wolf K and Malinverni R | Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. | 1999 | Antimicrob. Agents Chemother. | pmid:10348778 |